Literature DB >> 1704654

Peptide mapping of neutralizing and nonneutralizing epitopes of duck hepatitis B virus pre-S polypeptide.

S Yuasa1, R C Cheung, Q Pham, W S Robinson, P L Marion.   

Abstract

Antibodies to the envelope proteins of duck hepatitis B virus neutralize viral infection in vitro. Using a library of murine monoclonal antibodies (Mabs) against the envelope proteins, we previously identified four neutralizing and two non-neutralizing epitopes on the pre-S region of the large envelope proteins. In this study we report the localization of all but one of these epitopes at the amino acid level. All but 28 nucleotides of the pre-S and S genes were cloned in pUC vectors and expressed in Escherichia coli. All Mabs in this study reacted with the expressed gene products in Western blots. Deletion mutants of the pre-S region were generated and their expressed products tested on Western blots for reactivity with the Mabs. Of the three epitopes involved in neutralization, the epitope found to be immunodominant in convalescent ducks was localized to nine amino acids of the middle portion of the pre-S gene product, while a second epitope was mapped to nine amino acids upstream of the immunodominant epitope and the third epitope to seven amino acids adjacent to the S gene. One of the two non-neutralizing epitopes was located between the two groups of neutralizing epitopes while the other mapped to the same region as one of the neutralizing epitopes. Our data indicate that several regions of the pre-S polypeptide may play a role in neutralization of hepadnaviruses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1704654     DOI: 10.1016/0042-6822(91)90465-n

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

Review 1.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

Review 2.  Viral and cellular determinants involved in hepadnaviral entry.

Authors:  Dieter Glebe; Stephan Urban
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

3.  Dual topology of the large envelope protein of duck hepatitis B virus: determinants preventing pre-S translocation and glycosylation.

Authors:  I Swameye; H Schaller
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  Enhancement of hepatitis B virus infection by noninfectious subviral particles.

Authors:  M Bruns; S Miska; S Chassot; H Will
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

5.  Characterization of a 120-Kilodalton pre-S-binding protein as a candidate duck hepatitis B virus receptor.

Authors:  J S Li; S P Tong; J R Wands
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  Topology of the large envelope protein of duck hepatitis B virus suggests a mechanism for membrane translocation during particle morphogenesis.

Authors:  J T Guo; J C Pugh
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

7.  Interaction between duck hepatitis B virus and a 170-kilodalton cellular protein is mediated through a neutralizing epitope of the pre-S region and occurs during viral infection.

Authors:  S Tong; J Li; J R Wands
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product.

Authors:  Y L Lin; L A Borenstein; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor.

Authors:  U Klingmüller; H Schaller
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

10.  Identification of antigenic regions of duck hepatitis B virus core protein with antibodies elicited by DNA immunization and chronic infection.

Authors:  A Thermet; M Robaczewska; C Rollier; O Hantz; C Trepo; G Deleage; L Cova
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.